Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin's Lymphoma

By Fagnoni Philippe   Milpied Noel  

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 55-68

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Cardioprotective Strategies in Patients with Aggressive Non-Hodgkin’s Lymphoma

By Limat Samuel   Demesmay Karine  

Clinical Drug Investigation, Vol. 25, Iss. 11, 2005-01 ,pp. : 719-729

Adis International

Access to resources Recommend Favorite

Novel treatment strategies for aggressive non-Hodgkin’s lymphoma

By Fayad Luis   Younes Anas  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 6, 2006-04 ,pp. : 733-748

Informa Healthcare

Access to resources Recommend Favorite

Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma

By Chen Yi-Bin   Batchelor Tracy   Li Shuli   Hochberg Ephraim   Brezina Mark   Jones Sooae   Del Rio Candice   Curtis Morgan   Ballen Karen K.   Barnes Jeffrey   Chi Andrew S.   Dietrich Jorg   Driscoll Jessica   Gertsner Elizabeth R.   Hochberg Fred   LaCasce Ann S.   McAfee Steven L.   Spitzer Thomas R.   Nayak Lakshmi   Armand Philippe  

Cancer, Vol. 121, Iss. 2, 2015-01 ,pp. : 226-233

Blackwell Publishing

Access to resources Recommend Favorite

Treatment advances in non-Hodgkin’s lymphoma

By Tan B.R.   Bartlett N.L.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 451-465

Informa Healthcare

Access to resources Recommend Favorite